Literature DB >> 11559573

Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor.

S W Nam1, T Clair, Y S Kim, A McMarlin, E Schiffmann, L A Liotta, M L Stracke.   

Abstract

Autotaxin [ATX (NPP-2)], originally isolated as a tumor motility-stimulating protein, has recently been shown to augment tumor aggressiveness. Specifically, atx-transfected, ras-transformed NIH3T3 cell lines have been shown to be more invasive, tumorigenic, and metastatic than mock-transfected ras-transformed control cells. In addition, the atx-transfected ras-transformed cell lines appeared to produce tumors that were much more hyperemic than those formed by appropriate control cells. This observation led to the present study, in which we demonstrate that ATX modulates angiogenesis both directly and indirectly. We have used a murine in vivo angiogenesis model in which treated Matrigel plugs are injected s.c. into athymic nude BALB/c mice. Using the same transfected cell lines as before, we found that mixing atx-transfected ras-transformed NIH3T3 cells into the Matrigel resulted in greater new blood vessel formation than control cells. Similarly, mixing purified ATX into the Matrigel resulted in new blood vessel formation within the plug, similar to that produced by vascular endothelial growth factor. Mechanistically, ATX is not a strong chemoattractant for human endothelial cells (HUVECs); however, it strongly stimulates motility in human coronary artery smooth muscle cells. In addition, ATX stimulates HUVECs grown on Matrigel to form tubules, much like vascular endothelial growth factor. Both of these normal cell types are shown to express and secrete ATX. In HUVECs, ATX expression is up-regulated by basic fibroblast growth factor in a time-dependent manner. This up-regulation also extends to secretion of enzymatically active protein, as demonstrated by Western blot analysis and quantification of type-1 phosphodiesterase activity. These results establish the presence of ATX in HUVECs and coronary artery smooth muscle cells and specify ATX as a novel angiogenic factor, suggesting that ATX could contribute to the metastatic cascade through multiple mechanisms, perhaps by supporting an invasive microenvironment for both normal and tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559573

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  71 in total

1.  Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1.

Authors:  Rik Gijsbers; Hugo Ceulemans; Mathieu Bollen
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

2.  Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2.

Authors:  Anisoara Cimpean; Cristiana Stefan; Rik Gijsbers; Willy Stalmans; Mathieu Bollen
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

3.  Cardiac myocyte differentiation: the Nkx2.5 and Cripto target genes in P19 clone 6 cells.

Authors:  Hailing Liu; Thomas M Harris; Hyung H Kim; Geoffrey Childs
Journal:  Funct Integr Genomics       Date:  2005-04-02       Impact factor: 3.410

4.  Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.

Authors:  Hongjuan Zhao; Cristiane F Ramos; James D Brooks; Donna M Peehl
Journal:  J Cell Physiol       Date:  2007-01       Impact factor: 6.384

5.  Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.

Authors:  Peng Cui; Jose L Tomsig; William F McCalmont; Sangderk Lee; Christopher J Becker; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

6.  Engineering vascularized tissues using natural and synthetic small molecules.

Authors:  Lauren S Sefcik; Caren E Petrie Aronin; Edward A Botchwey
Journal:  Organogenesis       Date:  2008-10       Impact factor: 2.500

7.  Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.

Authors:  Gilles Ferry; Edwige Tellier; Anne Try; Sandra Grés; Isabelle Naime; Marie Françoise Simon; Marianne Rodriguez; Jérémie Boucher; Ivan Tack; Stéphane Gesta; Pascale Chomarat; Marc Dieu; Martine Raes; Jean Pierre Galizzi; Philippe Valet; Jean A Boutin; Jean Sébastien Saulnier-Blache
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

8.  Reduced expression of autotaxin predicts survival in uveal melanoma.

Authors:  Arun D Singh; Karen Sisley; Yaomin Xu; Jianbo Li; Pieter Faber; Sarah J Plummer; Hardeep S Mudhar; Ian G Rennie; Patricia M Kessler; Graham Casey; Bryan G Williams
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

Review 9.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08

10.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Authors:  Lauren P Saunders; Amy Ouellette; Russ Bandle; William Chozen Chang; Hongwen Zhou; Raj N Misra; Enrique M De La Cruz; Demetrios T Braddock
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.